<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Mol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Mol Hepatol</journal-id><journal-id journal-id-type="publisher-id">CMH</journal-id><journal-title-group><journal-title>Clinical and Molecular Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2287-2728</issn><issn pub-type="epub">2287-285X</issn><publisher><publisher-name>The Korean Association for the Study of the Liver</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6435966</article-id><article-id pub-id-type="pmid">30441889</article-id><article-id pub-id-type="doi">10.3350/cmh.2018.1007</article-id><article-id pub-id-type="publisher-id">cmh-2018-1007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Radiomics and radiogenomics of primary liver cancers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jeong</surname><given-names>Woo Kyoung</given-names></name><xref ref-type="aff" rid="af1-cmh-2018-1007"><sup>1</sup></xref><xref ref-type="aff" rid="af2-cmh-2018-1007"><sup>2</sup></xref><xref ref-type="aff" rid="af3-cmh-2018-1007"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3857-9735</contrib-id><name><surname>Jamshidi</surname><given-names>Neema</given-names></name><xref ref-type="corresp" rid="c1-cmh-2018-1007"/><xref ref-type="aff" rid="af1-cmh-2018-1007"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Felker</surname><given-names>Ely Richard</given-names></name><xref ref-type="aff" rid="af1-cmh-2018-1007"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Raman</surname><given-names>Steven Satish</given-names></name><xref ref-type="aff" rid="af1-cmh-2018-1007"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>David Shinkuo</given-names></name><xref ref-type="aff" rid="af1-cmh-2018-1007"><sup>1</sup></xref></contrib><aff id="af1-cmh-2018-1007">
<label>1</label>Department of Radiological Science, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, <country>USA</country></aff><aff id="af2-cmh-2018-1007">
<label>2</label>Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, <country>Korea</country></aff><aff id="af3-cmh-2018-1007">
<label>3</label>Department of Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, <country>Korea</country></aff></contrib-group><author-notes><corresp id="c1-cmh-2018-1007">Corresponding author : Neema Jamshidi Department of Radiological Science, David Geffen School of Medicine, University of California Los Angeles, 757 Westwood Avenue, Suite 2125, Los Angeles, CA 90095, USA Tel: +1-310-794-1411, Fax: +1-310-267-3631 E-mail: <email>NJamshidi@mednet.ucla.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>16</day><month>11</month><year>2018</year></pub-date><volume>25</volume><issue>1</issue><fpage>21</fpage><lpage>29</lpage><history><date date-type="received"><day>9</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 by The Korean Association for the Study of the Liver</copyright-statement><copyright-year>2019</copyright-year><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Concurrent advancements in imaging and genomic biomarkers have created opportunities to identify non-invasive imaging surrogates of molecular phenotypes. In order to develop such imaging surrogates radiomics and radiogenomics/imaging genomics will be necessary; there has been consistent progress in these fields for primary liver cancers. In this article we evaluate the current status of the field specifically with regards to hepatocellular carcinoma and intrahepatic cholangiocarcinoma, highlighting some of the up and coming results that were presented at the annual Radiological Society of North America Conference in 2017. There are an increasing number of studies in this area with a bias towards quantitative feature measurement, which is expected to benefit reproducibility of the findings and portends well for the future development of biomarkers for diagnosis, prognosis, and treatment response assessment. We review some of the advancements and look forward to some of the exciting future applications that are anticipated as the field develops.</p></abstract><kwd-group><kwd>Hepatocellular carcinoma</kwd><kwd>Cholangiocarcinoma</kwd><kwd>Tumor biomarker</kwd><kwd>Computed tomography</kwd><kwd>Genomics</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Clinical imaging modalities, such as computed tomography (CT), positron emission tomography, or magnetic resonance (MR) imaging, are critical cornerstones in diagnosis and management of modern oncology [<xref rid="b1-cmh-2018-1007" ref-type="bibr">1</xref>-<xref rid="b3-cmh-2018-1007" ref-type="bibr">3</xref>]. The maturity of these modalities and protocols of implementation have reached such a degree of sophistication, that properly obtained studies can supplant the need for a tissue biopsy in some diseases, such as the Liver Imaging Reporting And Data System for hepatocellular carcinoma (HCC) [<xref rid="b4-cmh-2018-1007" ref-type="bibr">4</xref>,<xref rid="b5-cmh-2018-1007" ref-type="bibr">5</xref>]. Even though the diagnostic protocol for liver cancer is increasingly refined, the prognosis of liver cancers remains unsatisfactory, which is the second most common cause of death from cancer worldwide [<xref rid="b6-cmh-2018-1007" ref-type="bibr">6</xref>]. Moreover, it is highlighted that variable biologic behavior of liver cancers affects patients&#x02019; survival, and the tumoral heterogeneity can be also an important clue in determining the likelihood of a clinical response to treatment [<xref rid="b7-cmh-2018-1007" ref-type="bibr">7</xref>,<xref rid="b8-cmh-2018-1007" ref-type="bibr">8</xref>]. Thus, the trend of diagnosis and treatment for liver cancers is changing to be determined by significant biological and genomic characteristics of the tumors, and imaging can be also a method to find these characteristics [<xref rid="b9-cmh-2018-1007" ref-type="bibr">9</xref>-<xref rid="b12-cmh-2018-1007" ref-type="bibr">12</xref>].</p><p>In contrast to serologic markers, the majority of imaging findings reported from radiologic studies involves qualitative or descriptive features. Moreover, the interobserver variability when radiologists define the imaging findings remains an unresolved issue [<xref rid="b13-cmh-2018-1007" ref-type="bibr">13</xref>]. Recently, new research methods to explore imaging biomarkers through objective and quantitative analyses of medical images including radiologic studies, have been developed into an academic discipline that studies the association of the imaging parameters with patient information, and several studies have been published in a variety of carcinomas [<xref rid="b14-cmh-2018-1007" ref-type="bibr">14</xref>,<xref rid="b15-cmh-2018-1007" ref-type="bibr">15</xref>].</p><p>However, this state-of-the-art method is still in its infancy, especially in the liver cancer research; various attempts have been made and presented in the annual meeting of Radiological Society of North America (RSNA) in 2017. This review article focuses on the preliminary clinical application of radiomics, and radiogenomics (or imaging genomics) for primary liver cancers, such as HCC and intrahepatic cholangiocarcinoma (ICC).</p></sec><sec><title>What are radiomics, radiogenomics, and imaging genomics?</title><p>Radiomics is a method of research that extracts quantitative radiologic data from medical images (radiomic data) and explores the correlation with clinical outcomes [<xref rid="b14-cmh-2018-1007" ref-type="bibr">14</xref>]. Radiogenomics (or imaging genomics) also aims to identify relationships between semantic as well as quantitative image data with genome and molecular measurements in order to construct association maps that can in turn be correlated with outcome or other clinical measures [<xref rid="b15-cmh-2018-1007" ref-type="bibr">15</xref>-<xref rid="b17-cmh-2018-1007" ref-type="bibr">17</xref>]. A requisite for both radiomics and radiogenomics is the identification of an objective manner to transform the imaging features into digital data, which is also important for insuring reproducibility. The general radiomics workflow involves, 1) acquisition of images, 2) identification of region of interest (by human or machine learning), 3) segmentation of region of interest (by automatic, semiautomatic, or manual drawing), 4) extraction of imaging features, and 5) mining the data to develop model to predict clinical outcomes (<xref rid="f1-cmh-2018-1007" ref-type="fig">Fig. 1</xref>).</p><p>For radiomics and radiogenomics, it is possible to analyze the medical images archived in the imaging server of the hospital retrospectively, and the more imaging database has sufficient data, the more accurate predictive radiomic model can be made. However, the variability of imaging quality and technical parameters for image acquisition may influence the image features and results of predictive models.</p></sec><sec><title>Radiological imaging traits: quantitative versus qualitative methods</title><p>The gold standard of radiologic image interpretation continues to be expert (radiologist) based reads, in spite of digital acquisition (or conversion) of clinical imaging data. In order to convert these images into parametric data objectively, it should be helped by specific analytic method, feature analysis (FA). FA is a quantitative method of objectively assessing tumor heterogeneity or parenchymal change in specific disease by exploring the distribution and connection of pixel or voxel gray levels in the CT image [<xref rid="b18-cmh-2018-1007" ref-type="bibr">18</xref>]. There are several parts, such as the gray-level frequency distribution from the pixel intensity histogram in a given region of interest, a co-occurrence matrix which considers the location of pixels and spatial relationship between pixels, and neighborhood gray-tone difference matrices which examine location and relationship between three or more pixels. In addition, model-based and transform-based methods are used for FA (<xref rid="f2-cmh-2018-1007" ref-type="fig">Fig. 2</xref>) [<xref rid="b19-cmh-2018-1007" ref-type="bibr">19</xref>].</p><p>Performance of quantitative analyses has multiple prerequisites. First of all, reasonable segmentation of the tumor should precede the FA. Segmentation is the most critical component because the subsequent feature data are generated from the segmented volumes, but it is still challenging due to indistinct border of the tumors [<xref rid="b16-cmh-2018-1007" ref-type="bibr">16</xref>]. At this step, it is vulnerable to be disturbed by reviewer&#x02019;s subjectivity; therefore, automatic or semi-automatic segmentation methods are preferred to manual methods [<xref rid="b20-cmh-2018-1007" ref-type="bibr">20</xref>], especially for liver cancers of which tumor-parenchyma differentiation may be not clear compared with lung and breast cancers. Second, denoising and gray-level standardization can affect the analytic result, especially second- and high-order statistics, thus these should be performed properly in the pre-processing steps to aid in reproducibility of the analysis.</p><p>One advantage of descriptive or qualitative features is that they frequently describe physiological or biological processes. For example, there is a largely accepted explanation for arterial phase enhancement of HCC masses in contrast-enhanced CT and MR images. The development of HCC frequently involves neovascularization of unpaired arteries that do not have associated portal tracts [<xref rid="b21-cmh-2018-1007" ref-type="bibr">21</xref>,<xref rid="b22-cmh-2018-1007" ref-type="bibr">22</xref>], thus increasing arterial flow through the unpaired artery as compensation for decrease of portal flow in the tumor. Consequently, contrast media goes into the tumor early on the arterial phase and goes out of the tumor through veins on following phases, called as wash-out [<xref rid="b23-cmh-2018-1007" ref-type="bibr">23</xref>]. Nowadays, these findings have been considered as hallmarks for imaging diagnosis of HCC [<xref rid="b4-cmh-2018-1007" ref-type="bibr">4</xref>,<xref rid="b5-cmh-2018-1007" ref-type="bibr">5</xref>]. While it is often reassuring when such features have a demonstrated (patho-)physiological description, a challenges is the difficulty with inter-observer , and even intra-observer, variability [<xref rid="b5-cmh-2018-1007" ref-type="bibr">5</xref>].</p></sec><sec><title>Biologic and genomic characteristics of liver cancers</title><p>HCC is the most common primary cancer in the liver. It is known to be a quiet killer with minimal symptoms at the early stages of disease, frequently occurring in the context of hepatitis infections and cirrhosis leading to end-stage liver disease, in addition to largely unknown tumor genetic factors. Current staging systems, such as Barcelona Clinic Liver Cancer staging system, do not take into account the histologic and molecular characteristics of the tumor [<xref rid="b9-cmh-2018-1007" ref-type="bibr">9</xref>].</p><p>According to recent studies, HCCs exhibit intra-individual and inter-individual genetic heterogeneity. Predicting biologic behavior of HCC is essential for an appropriate treatment, and investigators have found that patient prognosis is not only related to size of tumor and multiplicity, but also the pathologic features such as histologic grade of tumor, microvessel density, microscopic vascular invasion (MVI), and epithelial-mesenchymal transition (EMT) [<xref rid="b24-cmh-2018-1007" ref-type="bibr">24</xref>-<xref rid="b26-cmh-2018-1007" ref-type="bibr">26</xref>].</p><p>Histologic grade of HCC accounts for a combination of structural and cellular features and is a significant predictor. According to a meta-analysis of 114 related articles, poor tumor differentiation correlated with worse prognosis [<xref rid="b27-cmh-2018-1007" ref-type="bibr">27</xref>]. However, there was a limitation of divergences and inaccuracies led by a non-standardized grade distribution. Microvessel density, which allows semi-quantitative assessment of tumor neovascularization (CD31, CD34, and von Willebrand Factor), is known as a significant prognostic factor. Vascular endothelial growth factors (VEGFs) and hypoxia-inducible factors (HIFs) are also negative prognostic markers related to reduce overall survival and recurrence-free survival after tumor resection [<xref rid="b28-cmh-2018-1007" ref-type="bibr">28</xref>].</p><p>MVI is another well-known factor suggesting poor prognosis. In the large-scale retrospective study which observed transplanted patients&#x02019; survival, the authors revealed a doubling in the hazard of death was associated with the presence of MVI [<xref rid="b29-cmh-2018-1007" ref-type="bibr">29</xref>]. EMT is another pathologic feature to predict prognosis and it increases invasiveness of tumor and metastatic potential [<xref rid="b30-cmh-2018-1007" ref-type="bibr">30</xref>,<xref rid="b31-cmh-2018-1007" ref-type="bibr">31</xref>].</p><p>In terms of genomic markers, in order to accurately predict therapeutic response of targeted therapy based on tumor molecular profiles, there have been efforts to identify critical molecular subclasses with different prognostic consequence, and associated genetic or epigenetic drivers of specific subclasses.</p><p>Some investigators have proposed molecular classifications of HCC using mRNA-based gene expression based on biological processes (e.g. proliferation) and protein markers (e.g. EpCAM and cytokeratin 19 [CK19]) [<xref rid="b32-cmh-2018-1007" ref-type="bibr">32</xref>]. Villanueva et al. focused on both the tumor and nontumoral-adjacent cirrhotic tissue in order to identify a genomic signature predictive of patients&#x02019; outcome, and they suggested a model for prediction of recurrent HCC combining clinical, pathology, and genomic data [<xref rid="b33-cmh-2018-1007" ref-type="bibr">33</xref>].</p><p>ICC is another aggressive primary liver cancer and new studies are identifying pathologic biomarkers that reflect the biological behavior of the tumor. Overexpression of epidermal growth factor receptor (EGFR) was an independent prognostic parameter along with tumor stage [<xref rid="b34-cmh-2018-1007" ref-type="bibr">34</xref>]. EGFR, VEGF, and human epidermal growth factor receptor 2 were also significantly related to macroscopic type, nodal metastasis, lymphatic vessel invasion, perineural invasion and tumor stage [<xref rid="b35-cmh-2018-1007" ref-type="bibr">35</xref>].</p><p>KRAS mutation was found in up to 40% of cholangiocarcinoma, but predominantly in perihilar and distal tumors [<xref rid="b36-cmh-2018-1007" ref-type="bibr">36</xref>]. Because direct therapeutic inhibition of KRAS is difficult, targeted therapy aims at modulation of downstream signaling along the KRAS pathway. Recently, Graham et al. identified FGFR2 translocation in ICC, and it could be benefited from FGFR-targeted therapy [<xref rid="b37-cmh-2018-1007" ref-type="bibr">37</xref>].</p><p>Like HCC, microvessel density and EMT may play a role as biomarkers to indicate prognosis of ICC. Microvessel density and lymphatic microvessel density were frequently displayed in advanced ICC, and the patients of which microvessel density was high had an inferior curative resection rate and frequently developed recurrence [<xref rid="b38-cmh-2018-1007" ref-type="bibr">38</xref>]. In addition, the high expression of N-cadherin and S100A4, the pathologic evidences of EMT, were independently significant prognostic factors in ICC [<xref rid="b39-cmh-2018-1007" ref-type="bibr">39</xref>].</p></sec><sec><title>Where do we stand on the radiomics and radiogenomics for primary liver cancer?</title><p>There are limited quantitative analyses of imaging studies in the hepatic tumors to date although some researchers have focused on texture analysis. Most of the studies have focused on the relationship between imaging traits and clinical characteristics including survival, recurrence, and treatment response after chemotherapy. In contrast, some studies dealt with the relationship between the genomic signatures and imaging findings (without texture analysis); therefore, radiogenomic analysis for liver cancer is very rare so far (<xref rid="t1-cmh-2018-1007" ref-type="table">Table 1</xref>) [<xref rid="b40-cmh-2018-1007" ref-type="bibr">40</xref>,<xref rid="b41-cmh-2018-1007" ref-type="bibr">41</xref>].</p><p>The majority of the studies have centered on HCC, and been based on CT texture with only some studies which investigated the role of MRI [<xref rid="b16-cmh-2018-1007" ref-type="bibr">16</xref>]. At the 2017 RSNA Conference, there were several presentations about radiomics of HCC using MRI, especially gadoxetic acid-enhanced MRI.</p><sec><title>HCC</title><p>The first radiogenomic study of HCC was performed in 2007 [<xref rid="b10-cmh-2018-1007" ref-type="bibr">10</xref>] and involved measurement of quantitative as well as semantic imaging features. They found that combination of 28 imaging traits could reconstruct the variation of all 116 gene models, about 80% of global gene expression profiles, revealing cell proliferation, liver synthetic function, and patient prognosis. Among the imaging traits, the presence of internal arteries and the absence of a hypodense halo were associated with MVI genomic signatures that were comprised of genes involved in cell proliferation (CDK, CDC20, MCM5) and matrix invasion (ADAMTS1, MMP14, SPARCL1). On a subsequent study, the CT-based imaging traits were evaluated to predict the presence of MVI on pathologic specimen, and additional imaging trait, the absence of tumor-liver difference, was considered the third imaging trait for &#x0201c;radiogenomic venous invasion&#x0201d; imaging signature as well as the established two imaging traits. This signature was not only accurate to diagnose MVI but associated with lower overall survival [<xref rid="b11-cmh-2018-1007" ref-type="bibr">11</xref>].</p><p>Villanueva et al. [<xref rid="b33-cmh-2018-1007" ref-type="bibr">33</xref>] investigated the genomic features of HCC and peritumoral tissue that were associated with patients&#x02019; outcome, who tried to explore the relationship between imaging trait and genomic signatures [<xref rid="b42-cmh-2018-1007" ref-type="bibr">42</xref>]. Patients who underwent pre-operative CT or MR imaging before surgery as well as transcriptome profiling were assessed 11 qualitative and four quantitative (size, enhancement ratios, wash-out ratio, tumor-to-liver contrast ratio) imaging traits. Several imaging traits including infiltrative pattern and macrovascular invasion were associated with gene signatures of aggressive HCC phenotype such as proliferative signatures and CK19 signature.</p><p>More recently a radiomics signature derived from texture analysis was proposed to be a surrogate for MVI in HCC, prediction of patients&#x02019; survival, and early recurrence [<xref rid="b43-cmh-2018-1007" ref-type="bibr">43</xref>-<xref rid="b45-cmh-2018-1007" ref-type="bibr">45</xref>]. This study involved 28 HCC patients who underwent resection and evaluated some imaging textures and &#x0201c;delta features&#x0201d; defined as the absolute difference or the ratio calculated from all pairs of imaging phases (e.g. precontrast minus arterial phase Hounsfield units) [<xref rid="b43-cmh-2018-1007" ref-type="bibr">43</xref>]. Among 464 features, single and delta features between arterial and portal-venous phases were robust to detect MVI. Another research group published that contrast-enhanced MR-based texture analysis could differentiate pathologic grade [<xref rid="b46-cmh-2018-1007" ref-type="bibr">46</xref>]. Forty-six patients who performed contrast-enhanced MRI before tumor resection were enrolled and arterial phase images were used for analysis. Histological low-grade HCCs had increased mean intensity and decreased gray-level run-length non-uniformity in four directions. This suggest that internal heterogeneity could be an imaging feature reflecting high-grade HCC, which has poor clinical prognosis. Recently, a study group tried to explore the CT-based radiomics data which related to key genomic information such as doxorubicin-resistant genes (TP53, TOP2A, CTNNB1, CDKN2A and AKT1), and they identified radiomics signatures to successfully discriminate these chemo-resistant genes [<xref rid="b41-cmh-2018-1007" ref-type="bibr">41</xref>].</p><p>The majority of studies to date have focused on CT imaging features, however, now several MR imaging based studies are emerging and features associated with MVI have been found, such as decreased apparent diffusion coefficient (ADC) on diffusion weighted imaging [<xref rid="b47-cmh-2018-1007" ref-type="bibr">47</xref>], peritumoral enhancement, non-smooth tumor margin [<xref rid="b48-cmh-2018-1007" ref-type="bibr">48</xref>], and peritumoral hypointensity on hepatobiliary phase imaging following gadoxetic acid injection [<xref rid="b49-cmh-2018-1007" ref-type="bibr">49</xref>]. There are some MR imaging sequences, such as diffusion, that can provide information that is not measurable by CT [<xref rid="b50-cmh-2018-1007" ref-type="bibr">50</xref>], thus radiomic MR features are of great interest. However, MR imaging is more vulnerable to imaging artifacts such as motion and magnetic susceptibility, thus reproducibility between different scanners and even the same scanner is a non-trivial challenge. Additionally the signal intensity of MR imaging is not easy to be digitalized compared to CT imaging (Hounsfield units), which is easy to be modulated and standardized for radiomic analyses.</p><p>Last year at the RSNA Conference (2017), three results on MR-based radiomics analysis for HCC were presented. Hui et al. sought to predict early recurrence after resection using MR imaging [<xref rid="b51-cmh-2018-1007" ref-type="bibr">51</xref>]. The study involved 57 patients that were separated into cohorts with early recurrence or not, using texture analysis of contrast and entropy in the arterial phase with 79% accuracy. Chen et al. showed texture analysis on the perfusion MR imaging could be associated with Edmudson-Steiner grades, and skewness of area under curve map was revealed as a potential marker to predict histologic grades [<xref rid="b52-cmh-2018-1007" ref-type="bibr">52</xref>]. Hectors et al. analyzed MR imaging texture on multiparametric MRI including blood oxygenation level dependent imaging and dynamic contrast enhanced-MRI, and investigated the correlation with HIF-1&#x003b1; and gene expression of Wnt target GLUL, pharmacological target FGFR4, stemness markers EpCAM and KRT19 and immune checkpoint PDCD1 [<xref rid="b53-cmh-2018-1007" ref-type="bibr">53</xref>].</p></sec><sec><title>Intrahepatic cholangiocarcinoma</title><p>To date there has only been one radiogenomics ICC study. 25 enrolled patients with histologically proven ICC were evaluated according to CT-based textures and immunochemistry findings suggesting tissue hypoxia, such as EGFR, VEGF, CD24, TP53, MDM2, MRP-1, HIF-1&#x003b1;, CA-IX, and GLUT1 [<xref rid="b12-cmh-2018-1007" ref-type="bibr">12</xref>]. Following multiple variable regression, three imaging phenotypes, entropy, correlation, and homogeneity, were significantly associated with EGFR expression and correlation phenotype was associated with VEGF expression level although visual (qualitative) features were not associated with all of hypoxia markers. Another retrospective study tried to reveal which CT imaging phenotypes were associated with patient&#x02019;s survival and tumor genetics. CT imaging features were semantic and not quantitative; for example, central fibrosis, well-defined border, homogeneity of enhancement, central necrosis, liver surface retraction, vascular encasement, tumor thrombus, satellite lesions, intrahepatic metastasis and lymphadenopathy [<xref rid="b54-cmh-2018-1007" ref-type="bibr">54</xref>]. They found that necrosis, satellite nodule, and vascular encasement might be associated with a higher risk of death. However, they could not find the relationship between imaging features and genetic mutation such as IDH1 and KRAS gene.</p><p>Several published studies investigated imaging findings as related to patient outcome after resection. Asayama et al. evaluated delayed phase CT exams in a cohort of 32 patients and observed that the degree of enhancement correlated with the amount of fibrous stroma and the frequency of perineural invasion [<xref rid="b55-cmh-2018-1007" ref-type="bibr">55</xref>]. The survival of patients was also associated with the degree of enhancement [<xref rid="b55-cmh-2018-1007" ref-type="bibr">55</xref>]. Lee et al. explored that diffusion-weighted image could predict patients&#x02019; survival after resection [<xref rid="b56-cmh-2018-1007" ref-type="bibr">56</xref>]. Multivariate regression test revealed that degree of diffusion restriction was associated with patients&#x02019; survival, as well as histologic differentiation and intrahepatic metastasis on pathology.</p><p>A quantitative MR imaging study by Pandey et al. [<xref rid="b57-cmh-2018-1007" ref-type="bibr">57</xref>], explored imaging feature changes in 72 patients with unresectable ICC and underwent two MRI examinations before and after chemotherapy. Paradoxically, ADC values on the baseline study were lower and percent of viable tumor volume was higher in the group with longer survival (&#x0003e;10 months); it was hypothesized that radiologically viable tumor was more responsive to the chemotherapy.</p></sec></sec><sec><title>Future perspectives of radiomics: strengths and weaknesses</title><p>The preceding studies suggest that radiomic and radiogenomic approaches can be useful in gaining deeper insights into tumor genetics, biology, and clinical outcome. MR in particular likely has many new applications with the development of functional pulse sequences in addition the anatomical information, although standardization of protocols and image scans will continue to be a challenge for quantitative imaging analysis. It is conceivable that in the future, we will be able to use radiomics-based decision making tool to diagnose incidental hepatic lesion or to decide which treatment is best to the disease. Artificial intelligence and deep learning will also likely have roles to play in the future of radiomics and radiogenomics, particularly with regards to registration and segmentation of imaging studies.</p><p>Quantitative imaging approaches, including imaging texture analysis, reflect a departure from the historical, largely subjective approach for medical image interpretatin. The merit of this new method is that it is able to get digital information (data) from medical imaging and when performed under appropriate protocols, is more robust and reproducible than strictly human based interpretations, i.e., radiologist. A potential advantage is that information that may be &#x0201c;hidden&#x0201d; can be discerned with quantitative approaches. On the same token, there is a knowledge base that the radiologist has that radiomic based approaches have not yet achieved. Although there are too many variables to reliably predictive the future, it is likely that at a minimum these automated (or semi-automated) approaches will support the diagnostic and decision-making processes in medical imaging.</p><p>Nevertheless, there are remaining issues for clinical use. First, reproducibility is a very important issue [<xref rid="b14-cmh-2018-1007" ref-type="bibr">14</xref>]. This is related to many factors, such as imaging acquisition protocol, method of segmentation, method for extracting imaging features, and acquisition of clinical and genomic data. With respect to tumor markers, the standard reporting recommendations (REporting recommendations for tumour MARKer prognostic studies, REMARK) has been established for over 10 years [<xref rid="b58-cmh-2018-1007" ref-type="bibr">58</xref>]. In a similar vein, standardization of analysis methodologies in radiomics and radiogenomics will be necessary if these methods are to gain broad adoption in the imaging community. Second, estimating appropriate sample size is another important issue. While larger data sets and &#x0201c;big data&#x0201d; provide great promise to identify new predictors of survival and outcome, associations do not imply causality [<xref rid="b17-cmh-2018-1007" ref-type="bibr">17</xref>]. Third, although many radiomic studies have been implemented retrospectively, ideally a prospective study design is preferable. Additionally multisite hospitals may help increase the study size number and statistical power but at the cost of increased variability in standardization of protocols and data processing [<xref rid="b17-cmh-2018-1007" ref-type="bibr">17</xref>].</p></sec><sec><title>Conclusion</title><p>While oncologic radiomics and radiogenomics are in early stages of development there is much to be gained from continued investigations in order to maximize the utility of non-invasive diagnostic tests and potential molecular and genomic correlates of imaging features. Towards this end they may also advance the objectives of precision medicine as well as more cost effective healthcare.</p></sec></body><back><fn-group><fn fn-type="participating-researchers"><p><bold>Authors&#x02019; contribution</bold></p><p>WKJ and NJ outlined the manuscript, content, with subsequent revisions and edits.</p><p>WKJ drafted the manuscript.</p><p>All authors edited the manuscript.</p><p>All authors agreed on content.</p></fn></fn-group><fn-group><fn fn-type="COI-statement"><p><bold>Conflicts of Interest:</bold> The authors have no conflicts to disclose.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>ADC</term><def><p>apparent diffusion coefficient</p></def></def-item><def-item><term>CK</term><def><p>cytokeratin</p></def></def-item><def-item><term>CT</term><def><p>computed tomography</p></def></def-item><def-item><term>EGFR</term><def><p>epidermal growth factor receptor</p></def></def-item><def-item><term>EMT</term><def><p>epithelialmesenchymal transition</p></def></def-item><def-item><term>HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term>ICC</term><def><p>intrahepatic cholangiocarcinoma</p></def></def-item><def-item><term>MR</term><def><p>magnetic resonance</p></def></def-item><def-item><term>MVI</term><def><p>microscopic vascular invasion</p></def></def-item><def-item><term>RSNA</term><def><p>Radiological Society of North America</p></def></def-item><def-item><term>VEGF</term><def><p>vascular endothelial growth factor</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="b1-cmh-2018-1007"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hricak</surname><given-names>H</given-names></name></person-group><article-title>Oncologic imaging: a guiding hand of personalized cancer care</article-title><source>Radiology</source><year>2011</year><volume>259</volume><fpage>633</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">21493796</pub-id></element-citation></ref><ref id="b2-cmh-2018-1007"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Stanway</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>SR</given-names></name><name><surname>Constantinidou</surname><given-names>A</given-names></name></person-group><article-title>Imaging in oncology--over a century of advances</article-title><source>Nat Rev Clin Oncol</source><year>2012</year><volume>9</volume><fpage>728</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">23149892</pub-id></element-citation></ref><ref id="b3-cmh-2018-1007"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tirkes</surname><given-names>T</given-names></name><name><surname>Hollar</surname><given-names>MA</given-names></name><name><surname>Tann</surname><given-names>M</given-names></name><name><surname>Kohli</surname><given-names>MD</given-names></name><name><surname>Akisik</surname><given-names>F</given-names></name><name><surname>Sandrasegaran</surname><given-names>K</given-names></name></person-group><article-title>Response criteria in oncologic imaging: review of traditional and new criteria</article-title><source>Radiographics</source><year>2013</year><volume>33</volume><fpage>1323</fpage><lpage>1341</lpage><pub-id pub-id-type="pmid">24025927</pub-id></element-citation></ref><ref id="b4-cmh-2018-1007"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsayes</surname><given-names>KM</given-names></name><name><surname>Hooker</surname><given-names>JC</given-names></name><name><surname>Agrons</surname><given-names>MM</given-names></name><name><surname>Kielar</surname><given-names>AZ</given-names></name><name><surname>Tang</surname><given-names>A</given-names></name><name><surname>Fowler</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>2017 version of LI-RADS for CT and MR imaging: an update</article-title><source>Radiographics</source><year>2017</year><volume>37</volume><fpage>1994</fpage><lpage>2017</lpage><pub-id pub-id-type="pmid">29131761</pub-id></element-citation></ref><ref id="b5-cmh-2018-1007"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>C</given-names></name><name><surname>Rakhmonova</surname><given-names>G</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name></person-group><article-title>Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm</article-title><source>Clin Mol Hepatol</source><year>2016</year><volume>22</volume><fpage>296</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">27304548</pub-id></element-citation></ref><ref id="b6-cmh-2018-1007"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Agency for Research on Cancer</collab></person-group><article-title>GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012</article-title><comment>World Health Organization web site, <ext-link ext-link-type="uri" xlink:href="http://globocan.iarc.fr/Pages/fact_sheets_population.aspx">http://globocan.iarc.fr/Pages/fact_sheets_population.aspx</ext-link>. Accessed 6 Feb 2018</comment></element-citation></ref><ref id="b7-cmh-2018-1007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>DC</given-names></name><name><surname>Mayakonda</surname><given-names>A</given-names></name><name><surname>Dinh</surname><given-names>HQ</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genomic and epigenomic heterogeneity of hepatocellular carcinoma</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><fpage>2255</fpage><lpage>2265</lpage><pub-id pub-id-type="pmid">28302680</pub-id></element-citation></ref><ref id="b8-cmh-2018-1007"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>LC</given-names></name><name><surname>Hsu</surname><given-names>CH</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name></person-group><article-title>Tumor heterogeneity in hepatocellular carcinoma: facing the challenges</article-title><source>Liver Cancer</source><year>2016</year><volume>5</volume><fpage>128</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">27386431</pub-id></element-citation></ref><ref id="b9-cmh-2018-1007"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Gores</surname><given-names>GJ</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name></person-group><article-title>Hepatocellular carcinoma: clinical frontiers and perspectives</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>844</fpage><lpage>855</lpage><pub-id pub-id-type="pmid">24531850</pub-id></element-citation></ref><ref id="b10-cmh-2018-1007"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>E</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name><name><surname>Ooi</surname><given-names>C</given-names></name><name><surname>Adler</surname><given-names>AS</given-names></name><name><surname>Gollub</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Decoding global gene expression programs in liver cancer by noninvasive imaging</article-title><source>Nat Biotechnol</source><year>2007</year><volume>25</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">17515910</pub-id></element-citation></ref><ref id="b11-cmh-2018-1007"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>DS</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name><name><surname>Chan</surname><given-names>MG</given-names></name><name><surname>Korn</surname><given-names>RL</given-names></name><etal/></person-group><article-title>A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><fpage>792</fpage><lpage>800</lpage><pub-id pub-id-type="pmid">25930992</pub-id></element-citation></ref><ref id="b12-cmh-2018-1007"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadot</surname><given-names>E</given-names></name><name><surname>Simpson</surname><given-names>AL</given-names></name><name><surname>Do</surname><given-names>RK</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Shia</surname><given-names>J</given-names></name><name><surname>Allen</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Cholangiocarcinoma: correlation between molecular profiling and imaging phenotypes</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0132953</fpage><pub-id pub-id-type="pmid">26207380</pub-id></element-citation></ref><ref id="b13-cmh-2018-1007"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>MS</given-names></name><name><surname>Khalatbari</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>PS</given-names></name><name><surname>Maturen</surname><given-names>KE</given-names></name><name><surname>Kaza</surname><given-names>RK</given-names></name><name><surname>Wasnik</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Repeatability of diagnostic features and scoring systems for hepatocellular carcinoma by using MR imaging</article-title><source>Radiology</source><year>2014</year><volume>272</volume><fpage>132</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">24555636</pub-id></element-citation></ref><ref id="b14-cmh-2018-1007"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><name><surname>Ko</surname><given-names>ES</given-names></name><name><surname>Jeong</surname><given-names>WK</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Radiomics and imaging genomics in precision medicine</article-title><source>Precis Future Med</source><year>2017</year><volume>1</volume><fpage>10</fpage><lpage>31</lpage></element-citation></ref><ref id="b15-cmh-2018-1007"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>HX</given-names></name><name><surname>Lee</surname><given-names>AM</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name><name><surname>Maris</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Imaging genomics in cancer research: limitations and promises</article-title><source>Br J Radiol</source><year>2016</year><volume>89</volume><fpage>20151030</fpage><pub-id pub-id-type="pmid">26864054</pub-id></element-citation></ref><ref id="b16-cmh-2018-1007"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinker</surname><given-names>K</given-names></name><name><surname>Shitano</surname><given-names>F</given-names></name><name><surname>Sala</surname><given-names>E</given-names></name><name><surname>Do</surname><given-names>RK</given-names></name><name><surname>Young</surname><given-names>RJ</given-names></name><name><surname>Wibmer</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Background, current role, and potential applications of radiogenomics</article-title><source>J Magn Reson Imaging</source><year>2018</year><volume>47</volume><fpage>604</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">29095543</pub-id></element-citation></ref><ref id="b17-cmh-2018-1007"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilles</surname><given-names>RJ</given-names></name><name><surname>Kinahan</surname><given-names>PE</given-names></name><name><surname>Hricak</surname><given-names>H</given-names></name></person-group><article-title>Radiomics: images are more than pictures, they are data</article-title><source>Radiology</source><year>2016</year><volume>278</volume><fpage>563</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">26579733</pub-id></element-citation></ref><ref id="b18-cmh-2018-1007"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganeshan</surname><given-names>B</given-names></name><name><surname>Miles</surname><given-names>KA</given-names></name></person-group><article-title>Quantifying tumour heterogeneity with CT</article-title><source>Cancer Imaging</source><year>2013</year><volume>13</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">23545171</pub-id></element-citation></ref><ref id="b19-cmh-2018-1007"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubner</surname><given-names>MG</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name><name><surname>Sandrasegaran</surname><given-names>K</given-names></name><name><surname>Sahani</surname><given-names>DV</given-names></name><name><surname>Pickhardt</surname><given-names>PJ</given-names></name></person-group><article-title>CT texture analysis: definitions, applications, biologic correlates, and challenges</article-title><source>Radiographics</source><year>2017</year><volume>37</volume><fpage>1483</fpage><lpage>1503</lpage><pub-id pub-id-type="pmid">28898189</pub-id></element-citation></ref><ref id="b20-cmh-2018-1007"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Woo</surname><given-names>B</given-names></name><name><surname>Kuo</surname><given-names>MD</given-names></name><name><surname>Jamshidi</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name></person-group><article-title>Quality of radiomic features in glioblastoma multiforme: impact of semi-automated tumor segmentation software</article-title><source>Korean J Radiol</source><year>2017</year><volume>18</volume><fpage>498</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">28458602</pub-id></element-citation></ref><ref id="b21-cmh-2018-1007"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakashima</surname><given-names>O</given-names></name><name><surname>Sugihara</surname><given-names>S</given-names></name><name><surname>Kage</surname><given-names>M</given-names></name><name><surname>Kojiro</surname><given-names>M</given-names></name></person-group><article-title>Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins</article-title><source>Hepatology</source><year>1995</year><volume>22</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">7601399</pub-id></element-citation></ref><ref id="b22-cmh-2018-1007"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>International Consensus Group for Hepatocellular</surname><given-names>Neoplasia</given-names></name></person-group><article-title>Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>658</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">19177576</pub-id></element-citation></ref><ref id="b23-cmh-2018-1007"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name></person-group><article-title>CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects</article-title><source>Radiology</source><year>2014</year><volume>272</volume><fpage>635</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">25153274</pub-id></element-citation></ref><ref id="b24-cmh-2018-1007"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Libbrecht</surname><given-names>L</given-names></name><name><surname>Chu</surname><given-names>IS</given-names></name><name><surname>Kaposi-Novak</surname><given-names>P</given-names></name><name><surname>Calvisi</surname><given-names>DF</given-names></name><etal/></person-group><article-title>A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells</article-title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">16532004</pub-id></element-citation></ref><ref id="b25-cmh-2018-1007"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Peix</surname><given-names>J</given-names></name><name><surname>Chiang</surname><given-names>DY</given-names></name><name><surname>Cmargo</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gene expression in fixed tissues and outcome in hepatocellular carcinoma</article-title><source>N Eng J Med</source><year>2008</year><volume>359</volume><fpage>1995</fpage><lpage>2004</lpage></element-citation></ref><ref id="b26-cmh-2018-1007"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Toffanin</surname><given-names>S</given-names></name><name><surname>Lachenmayer</surname><given-names>A</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Minguez</surname><given-names>B</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Molecular classification and novel targets in hepatocellular carcinoma: recent advancements</article-title><source>Semin Liver Dis</source><year>2010</year><volume>30</volume><fpage>35</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20175032</pub-id></element-citation></ref><ref id="b27-cmh-2018-1007"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins-Filho</surname><given-names>SN</given-names></name><name><surname>Paiva</surname><given-names>C</given-names></name><name><surname>Azevedo</surname><given-names>RS</given-names></name><name><surname>Alves</surname><given-names>VAF</given-names></name></person-group><article-title>Histological grading of hepatocellular carcinoma-a systematic review of literature</article-title><source>Front Med (Lausanne)</source><year>2017</year><volume>4</volume><fpage>193</fpage><pub-id pub-id-type="pmid">29209611</pub-id></element-citation></ref><ref id="b28-cmh-2018-1007"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berretta</surname><given-names>M</given-names></name><name><surname>Cavaliere</surname><given-names>C</given-names></name><name><surname>Alessandrini</surname><given-names>L</given-names></name><name><surname>Stanzione</surname><given-names>B</given-names></name><name><surname>Facchini</surname><given-names>G</given-names></name><name><surname>Balestreri</surname><given-names>L</given-names></name><etal/></person-group><article-title>Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>14192</fpage><lpage>14220</lpage><pub-id pub-id-type="pmid">28077782</pub-id></element-citation></ref><ref id="b29-cmh-2018-1007"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Miceli</surname><given-names>R</given-names></name><name><surname>Bhoori</surname><given-names>S</given-names></name><name><surname>Schiavo</surname><given-names>M</given-names></name><name><surname>Mariani</surname><given-names>L</given-names></name><etal/></person-group><article-title>Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>35</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">19058754</pub-id></element-citation></ref><ref id="b30-cmh-2018-1007"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maetzel</surname><given-names>D</given-names></name><name><surname>Denzel</surname><given-names>S</given-names></name><name><surname>Mack</surname><given-names>B</given-names></name><name><surname>Canis</surname><given-names>M</given-names></name><name><surname>Went</surname><given-names>P</given-names></name><name><surname>Benk</surname><given-names>M</given-names></name><etal/></person-group><article-title>Nuclear signaling by tumour-associated antigen EpCAM</article-title><source>Nat Cell Biol</source><year>2009</year><volume>11</volume><fpage>162</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">19136966</pub-id></element-citation></ref><ref id="b31-cmh-2018-1007"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zijl</surname><given-names>F</given-names></name><name><surname>Zulehner</surname><given-names>G</given-names></name><name><surname>Petz</surname><given-names>M</given-names></name><name><surname>Schneller</surname><given-names>D</given-names></name><name><surname>Kornauth</surname><given-names>C</given-names></name><name><surname>Hau</surname><given-names>M</given-names></name><etal/></person-group><article-title>Epithelial-mesenchymal transition in hepatocellular carcinoma</article-title><source>Future Oncol</source><year>2009</year><volume>5</volume><fpage>1169</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">19852728</pub-id></element-citation></ref><ref id="b32-cmh-2018-1007"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Toffanin</surname><given-names>S</given-names></name><name><surname>Lachenmayer</surname><given-names>A</given-names></name><name><surname>Alsinet</surname><given-names>C</given-names></name><name><surname>Savic</surname><given-names>R</given-names></name><etal/></person-group><article-title>New strategies in hepatocellular carcinoma: genomic prognostic markers</article-title><source>Clin Cancer Res</source><year>2010</year><volume>16</volume><fpage>4688</fpage><lpage>4694</lpage><pub-id pub-id-type="pmid">20713493</pub-id></element-citation></ref><ref id="b33-cmh-2018-1007"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Battiston</surname><given-names>C</given-names></name><name><surname>Tovar</surname><given-names>V</given-names></name><name><surname>Sia</surname><given-names>D</given-names></name><name><surname>Alsinet</surname><given-names>C</given-names></name><etal/></person-group><article-title>Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma</article-title><source>Gastroenterology</source><year>2011</year><volume>140</volume><fpage>1501</fpage><lpage>1512</lpage><comment>e2</comment><pub-id pub-id-type="pmid">21320499</pub-id></element-citation></ref><ref id="b34-cmh-2018-1007"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YT</given-names></name><name><surname>Chang</surname><given-names>MC</given-names></name><name><surname>Huang</surname><given-names>KW</given-names></name><name><surname>Tung</surname><given-names>CC</given-names></name><name><surname>Hsu</surname><given-names>C</given-names></name><name><surname>Wong</surname><given-names>JM</given-names></name></person-group><article-title>Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan</article-title><source>J Gastroenterol Hepatol</source><year>2014</year><volume>29</volume><fpage>1119</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">24372748</pub-id></element-citation></ref><ref id="b35-cmh-2018-1007"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>D</given-names></name><name><surname>Ojima</surname><given-names>H</given-names></name><name><surname>Iwasaki</surname><given-names>M</given-names></name><name><surname>Hiraoka</surname><given-names>N</given-names></name><name><surname>Kosuge</surname><given-names>T</given-names></name><name><surname>Kasai</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><fpage>418</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">18087285</pub-id></element-citation></ref><ref id="b36-cmh-2018-1007"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mertens</surname><given-names>JC</given-names></name><name><surname>Rizvi</surname><given-names>S</given-names></name><name><surname>Gores</surname><given-names>Gores</given-names></name></person-group><article-title>Targeting cholangiocarcinoma</article-title><source>Biochim Biophys Acta</source><year>2018</year><issue>4 Pt B</issue><fpage>1454</fpage><lpage>1460</lpage></element-citation></ref><ref id="b37-cmh-2018-1007"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>RP</given-names></name><name><surname>Barr Fritcher</surname><given-names>EG</given-names></name><name><surname>Pestova</surname><given-names>E</given-names></name><name><surname>Schulz</surname><given-names>J</given-names></name><name><surname>Sitailo</surname><given-names>LA</given-names></name><name><surname>Vasmatzis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma</article-title><source>Hum Pathol</source><year>2014</year><volume>45</volume><fpage>1630</fpage><lpage>1638</lpage><pub-id pub-id-type="pmid">24837095</pub-id></element-citation></ref><ref id="b38-cmh-2018-1007"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thelen</surname><given-names>A</given-names></name><name><surname>Scholz</surname><given-names>A</given-names></name><name><surname>Weichert</surname><given-names>W</given-names></name><name><surname>Wiedenmann</surname><given-names>B</given-names></name><name><surname>Neuhaus</surname><given-names>P</given-names></name><name><surname>Gessner</surname><given-names>R</given-names></name><etal/></person-group><article-title>Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma</article-title><source>Am J Gastroenterol</source><year>2010</year><volume>105</volume><fpage>1123</fpage><lpage>1132</lpage><pub-id pub-id-type="pmid">19997097</pub-id></element-citation></ref><ref id="b39-cmh-2018-1007"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nitta</surname><given-names>T</given-names></name><name><surname>Mitsuhashi</surname><given-names>T</given-names></name><name><surname>Hatanaka</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>M</given-names></name><name><surname>Oba</surname><given-names>K</given-names></name><name><surname>Tsuchikawa</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prognostic significance of epithelial-mesenchymal transitionrelated markers in extrahepatic cholangiocarcinoma: comprehensive immunohistochemical study using a tissue microarray</article-title><source>Br J Cancer</source><year>2014</year><volume>111</volume><fpage>1363</fpage><lpage>1372</lpage><pub-id pub-id-type="pmid">25077440</pub-id></element-citation></ref><ref id="b40-cmh-2018-1007"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><etal/></person-group><article-title>Radiogenomics of hepatocellular carcinoma: multiregion analysis-based identification of prognostic imaging biomarkers by integrating gene data-a preliminary study</article-title><source>Phys Med Biol</source><year>2018</year><volume>63</volume><fpage>035044</fpage><pub-id pub-id-type="pmid">29311419</pub-id></element-citation></ref><ref id="b41-cmh-2018-1007"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>DL</given-names></name><name><surname>Kotrotsou</surname><given-names>A</given-names></name><name><surname>Niekamp</surname><given-names>AS</given-names></name><name><surname>Idris</surname><given-names>T</given-names></name><name><surname>Camejo</surname><given-names>DG</given-names></name><name><surname>Mazal</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>CT-based radiomics analysis of hepatocellular carcinoma patients to predict key genomic information [Abstract]</article-title><source>J Clin Oncol</source><year>2017</year><month>5</month><day>30</day><comment>doi: 10.1200/JCO.2017.35.15_suppl.e15623</comment></element-citation></ref><ref id="b42-cmh-2018-1007"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taouli</surname><given-names>B</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Kakite</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Tan</surname><given-names>PS</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group><article-title>Imagingbased surrogate markers of transcriptome subclasses and signatures in hepatocellular carcinoma: preliminary results</article-title><source>Eur Radiol</source><year>2017</year><volume>27</volume><fpage>4472</fpage><lpage>4481</lpage><pub-id pub-id-type="pmid">28439654</pub-id></element-citation></ref><ref id="b43-cmh-2018-1007"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakr</surname><given-names>S</given-names></name><name><surname>Echegaray</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>R</given-names></name><name><surname>Kamaya</surname><given-names>A</given-names></name><name><surname>Louie</surname><given-names>J</given-names></name><name><surname>Napel</surname><given-names>S</given-names></name><etal/></person-group><article-title>Noninvasive radiomics signature based on quantitative analysis of computed tomography images as a surrogate for microvascular invasion in hepatocellular carcinoma: a pilot study</article-title><source>J Med Imaging (Bellingham)</source><year>2017</year><volume>4</volume><fpage>041303</fpage><pub-id pub-id-type="pmid">28840174</pub-id></element-citation></ref><ref id="b44-cmh-2018-1007"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name></person-group><article-title>Texture analysis of baseline multiphasic hepatic computed tomography images for the prognosis of single hepatocellular carcinoma after hepatectomy: a retrospective pilot study</article-title><source>Eur J Radiol</source><year>2017</year><volume>90</volume><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">28583634</pub-id></element-citation></ref><ref id="b45-cmh-2018-1007"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>P</given-names></name><name><surname>Ye</surname><given-names>W</given-names></name><etal/></person-group><article-title>CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma</article-title><source>Abdom Radiol (NY)</source><year>2017</year><volume>42</volume><fpage>1695</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">28180924</pub-id></element-citation></ref><ref id="b46-cmh-2018-1007"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images</article-title><source>J Magn Reson Imaging</source><year>2017</year><volume>45</volume><fpage>1476</fpage><lpage>1484</lpage><pub-id pub-id-type="pmid">27626270</pub-id></element-citation></ref><ref id="b47-cmh-2018-1007"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name></person-group><article-title>Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging</article-title><source>Liver Transpl</source><year>2012</year><volume>18</volume><fpage>1171</fpage><lpage>1178</lpage><pub-id pub-id-type="pmid">22767394</pub-id></element-citation></ref><ref id="b48-cmh-2018-1007"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Renzulli</surname><given-names>M</given-names></name><name><surname>Brocchi</surname><given-names>S</given-names></name><name><surname>Cucchetti</surname><given-names>A</given-names></name><name><surname>Mazzotti</surname><given-names>F</given-names></name><name><surname>Mosconi</surname><given-names>C</given-names></name><name><surname>Sportoletti</surname><given-names>C</given-names></name><etal/></person-group><article-title>Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma?</article-title><source>Radiology</source><year>2016</year><volume>279</volume><fpage>432</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">26653683</pub-id></element-citation></ref><ref id="b49-cmh-2018-1007"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>AY</given-names></name><name><surname>Sinn</surname><given-names>DH</given-names></name><name><surname>Jeong</surname><given-names>WK</given-names></name><name><surname>Kim</surname><given-names>YK</given-names></name><name><surname>Kant</surname><given-names>TW</given-names></name><name><surname>Ha</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2018</year><volume>68</volume><fpage>1144</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">29410377</pub-id></element-citation></ref><ref id="b50-cmh-2018-1007"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>ES</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name></person-group><article-title>MRI features of hepatocellular carcinoma related to biologic behavior</article-title><source>Korean J Radiol</source><year>2015</year><volume>16</volume><fpage>449</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">25995679</pub-id></element-citation></ref><ref id="b51-cmh-2018-1007"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>TC</given-names></name><name><surname>Chuah</surname><given-names>TK</given-names></name><name><surname>Tan</surname><given-names>ZL</given-names></name><name><surname>Divya</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>CH</given-names></name></person-group><article-title>Predicting early recurrence of hepatocellular carcinoma with texture analysis of preoperative magnetic resonance imaging: a radiomics study [Abstract]</article-title><source>RSNA</source><year>2017</year><fpage>SSJ07</fpage><lpage>04</lpage></element-citation></ref><ref id="b52-cmh-2018-1007"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Duan</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>B</given-names></name></person-group><article-title>The value of texture analysis on perfusion-weighted magnetic resonance imaging for malignancy characterization of hepatocellular carcinoma [Abstract]</article-title><source>RSNA</source><year>2017</year><fpage>SSK07</fpage><lpage>04</lpage></element-citation></ref><ref id="b53-cmh-2018-1007"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hectors</surname><given-names>SJ</given-names></name><name><surname>Wagner</surname><given-names>M</given-names></name><name><surname>Bane</surname><given-names>O</given-names></name><name><surname>Besa</surname><given-names>C</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name><name><surname>Remark</surname><given-names>R</given-names></name><etal/></person-group><article-title>Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>2452</fpage><pub-id pub-id-type="pmid">28550313</pub-id></element-citation></ref><ref id="b54-cmh-2018-1007"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aherne</surname><given-names>EA</given-names></name><name><surname>Pak</surname><given-names>LM</given-names></name><name><surname>Goldman</surname><given-names>DA</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Jarnagin</surname><given-names>WR</given-names></name><name><surname>Simpson</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Intrahepatic cholangiocarcinoma: can imaging phenotypes predict survival and tumor genetics?</article-title><source>Abdom Radiol (NY)</source><year>2018</year><month>2</month><day>28</day><comment>doi: 10.1007/s00261-018-1505-4</comment></element-citation></ref><ref id="b55-cmh-2018-1007"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asayama</surname><given-names>Y</given-names></name><name><surname>Yoshimitsu</surname><given-names>K</given-names></name><name><surname>Irie</surname><given-names>H</given-names></name><name><surname>Tajima</surname><given-names>T</given-names></name><name><surname>Nishie</surname><given-names>A</given-names></name><name><surname>Hirakawa</surname><given-names>M</given-names></name><etal/></person-group><article-title>Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma</article-title><source>Radiology</source><year>2006</year><volume>238</volume><fpage>150</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">16304089</pub-id></element-citation></ref><ref id="b56-cmh-2018-1007"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kang</surname><given-names>TW</given-names></name><name><surname>Song</surname><given-names>KD</given-names></name><name><surname>Choi</surname><given-names>D</given-names></name><name><surname>Jang</surname><given-names>KT</given-names></name></person-group><article-title>Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker</article-title><source>Radiology</source><year>2016</year><volume>281</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">27115053</pub-id></element-citation></ref><ref id="b57-cmh-2018-1007"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>A</given-names></name><name><surname>Pandey</surname><given-names>P</given-names></name><name><surname>Varzaneh</surname><given-names>FN</given-names></name><name><surname>Zarghampour</surname><given-names>M</given-names></name><name><surname>Shao</surname><given-names>N</given-names></name><name><surname>Khoshpouri</surname><given-names>P</given-names></name><etal/></person-group><article-title>Volumetric functional MRI as new prognostic marker to predict survival in unresectable intrahepatic cholangiocarcinoma undergoing systemic chemotherapy: long term single institution outcomes [Abstract]</article-title><source>RSNA</source><year>2017</year><fpage>SSE07</fpage><lpage>02</lpage></element-citation></ref><ref id="b58-cmh-2018-1007"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McShane</surname><given-names>LM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name><name><surname>Taube</surname><given-names>SE</given-names></name><name><surname>Gion</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Reporting recommendations for tumor marker prognostic studies (REMARK)</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>1180</fpage><lpage>1184</lpage><pub-id pub-id-type="pmid">16106022</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-cmh-2018-1007" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The process of radiomics and radiogenomics. In comparison to the current conventional imaging study interpretation, radiomic and radiogenomic approaches require multiple processing steps (automated as well as semi-automated steps including registration, segmentation, region of interest selection, measurement, etc.). As the fields develop and methodologies become more standardized these steps may also become &#x0201c;implicit&#x0201d; in the image processing component, similar to the processing of raw computed tomography (CT) or magnetic resonance (MR) data before transmission to clinical PACS. Selected icons adapted and reprinted from Lubner et al.[<xref rid="b19-cmh-2018-1007" ref-type="bibr">19</xref>], with permission from Radiological Society of North America (RSNA). PACS, picture archiving and communication system.</p></caption><graphic xlink:href="cmh-2018-1007f1"/></fig><fig id="f2-cmh-2018-1007" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>An example of acquiring texture parameters through feature analysis. Following selection of an appropriate the region of interest (white arrow) of an image, (A) a histogram of gray-level intensity and distribution can be drawn. From the histogram, several statistical measures including mean, mean of the positive pixel, standard deviation can be calculated (A). The distributions of the measurements can further be characterized in terms of their (B) skewness, and (C) kurtosis. Modified and reprinted from Lubner et al.[<xref rid="b19-cmh-2018-1007" ref-type="bibr">19</xref>], with permission from Radiological Society of North America (RSNA).</p></caption><graphic xlink:href="cmh-2018-1007f2"/></fig><table-wrap id="t1-cmh-2018-1007" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Radiomics and radiogenomics (imaging genomics) studies of liver cancers published in literature</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" rowspan="1" colspan="1">Literature type</th><th align="center" valign="middle" rowspan="1" colspan="1">Radiomics</th><th align="center" valign="middle" rowspan="1" colspan="1">Country</th><th align="center" valign="middle" rowspan="1" colspan="1">Cancer type</th><th align="center" valign="middle" rowspan="1" colspan="1">Number of subject</th><th align="center" valign="middle" rowspan="1" colspan="1">Modality</th><th align="center" valign="middle" rowspan="1" colspan="1">Measurement type</th><th align="center" valign="middle" rowspan="1" colspan="1">Correlating dataset</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Xia W, et al. [<xref rid="b40-cmh-2018-1007" ref-type="bibr">40</xref>] (2018)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiogenomics</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">38</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Prognostic gene module, OS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Taouli B, et al. [<xref rid="b42-cmh-2018-1007" ref-type="bibr">42</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiogenomics</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">38</td><td align="center" valign="top" rowspan="1" colspan="1">CT, MR</td><td align="center" valign="top" rowspan="1" colspan="1">Semantic</td><td align="center" valign="top" rowspan="1" colspan="1">Gene signatures of aggressive HCC</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Banerjee S, et al. [<xref rid="b11-cmh-2018-1007" ref-type="bibr">11</xref>] (2015)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiogenomics</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">157</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Semantic</td><td align="center" valign="top" rowspan="1" colspan="1">Pathologic feature (MVI), OS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bakr S, et al. [<xref rid="b43-cmh-2018-1007" ref-type="bibr">43</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiomics</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Pathologic feature (MVI)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zhou Y, et al. [<xref rid="b45-cmh-2018-1007" ref-type="bibr">45</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiomics</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">215</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Early recurrence</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zhou W, et al. [<xref rid="b46-cmh-2018-1007" ref-type="bibr">46</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiomics</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">MR</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Histologic grade (Edmonson grade)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chen S, et al. [<xref rid="b44-cmh-2018-1007" ref-type="bibr">44</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiomics</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">61</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">OS, DFS</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sadot E, et al. [<xref rid="b12-cmh-2018-1007" ref-type="bibr">12</xref>] (2015)</td><td align="center" valign="top" rowspan="1" colspan="1">Article</td><td align="center" valign="top" rowspan="1" colspan="1">Radiomics</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">ICC</td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Immunostain for hypoxia markers</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">West DL, et al. [<xref rid="b41-cmh-2018-1007" ref-type="bibr">41</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Conference abstract</td><td align="center" valign="top" rowspan="1" colspan="1">Radiogenomics</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Gene of doxorubicin chemoresistance</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hui TC, et al. [<xref rid="b51-cmh-2018-1007" ref-type="bibr">51</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Conference abstract</td><td align="center" valign="top" rowspan="1" colspan="1">Radiomics</td><td align="center" valign="top" rowspan="1" colspan="1">Singapore</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">57</td><td align="center" valign="top" rowspan="1" colspan="1">MR</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Early recurrence</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chen J, et al. [<xref rid="b52-cmh-2018-1007" ref-type="bibr">52</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Conference abstract</td><td align="center" valign="top" rowspan="1" colspan="1">Radiogenomics</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">MR</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">Histologic grade (Edmonson grade)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hectors SJ, et al. [<xref rid="b53-cmh-2018-1007" ref-type="bibr">53</xref>] (2017)</td><td align="center" valign="top" rowspan="1" colspan="1">Conference abstract</td><td align="center" valign="top" rowspan="1" colspan="1">Radiogenomics</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">HCC</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="center" valign="top" rowspan="1" colspan="1">MR</td><td align="center" valign="top" rowspan="1" colspan="1">Quantitative</td><td align="center" valign="top" rowspan="1" colspan="1">GLUL, FGFR4, EpCAM, KRT19, PDCD1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aherne EA, et al. [<xref rid="b54-cmh-2018-1007" ref-type="bibr">54</xref>] (2018)</td><td align="center" valign="top" rowspan="1" colspan="1">Conference abstract</td><td align="center" valign="top" rowspan="1" colspan="1">Radiogenomics</td><td align="center" valign="top" rowspan="1" colspan="1">USA</td><td align="center" valign="top" rowspan="1" colspan="1">ICC</td><td align="center" valign="top" rowspan="1" colspan="1">66</td><td align="center" valign="top" rowspan="1" colspan="1">CT</td><td align="center" valign="top" rowspan="1" colspan="1">Semantic</td><td align="center" valign="top" rowspan="1" colspan="1">OS, DFS</td></tr></tbody></table><table-wrap-foot><fn><p>HCC, hepatocellular carcinoma; CT, computed tomography; OS, overall survival; MR, magnetic resonance; MVI, microscopic vascular invasion; DFS, disease-free survival; ICC, intrahepatic cholangiocarcinoma.</p></fn></table-wrap-foot></table-wrap></floats-group></article>